Ankündigung • Sep 26
Cardiac Biotech Solutions, Inc. Secures Health Canada License for MyCardia AT Device, Now Branded as CardioHolter AT Cardiac Biotech Solutions Inc. announced that its MyCardia AT device has been issued a Medical Device License (MDL) by Health Canada and is now approved for import into Canada, effective immediately. The device, rebranded as the CardioHolter AT, will be tested and distributed through CBSC's manufacturing partner, Nasiff Associates, located in Central Square, NY. Nasiff Associates is a Health Canada-licensed establishment operating under a certified ISO 13485 Quality Management System (QMS) that complies with Health Canada standards for Class II medical devices. CBSC's exclusive Canadian distributor, Your Heart Protector Corp. (Calgary, Alberta), has placed an initial order for CardioHolter AT devices totaling $375,000 USD. Delivery of the first 1,000 devices will occur upon completion of production (currently underway), with the balance scheduled for shipment within 90-120 days. In addition to revenue from device sales, CBSC has implemented a monthly rental program that provides recurring income whenever devices are deployed in hospitals and healthcare facilities. The program fees include access to the device, the AWS Cloud-based monitoring platform, and patient-facing mobile applications. Whether using standard landline telephone connections or newer cellular and WiFi-enabled technologies, patients can reliably transmit recorded ECG data to their physicians for timely review and diagnosis. This technology empowers physicians to achieve better patient outcomes, improved diagnoses, and enhanced quality of life regardless of a patient's location. The Company continues to advance the global commercialization of its MyCardia AT cardiac event monitoring platform, which integrates lightweight, easy-to-use wearable technology with AWS Cloud-based connectivity and mobile applications for iOS, Android, and WeChat. With regulatory clearance already secured in the United States and Canada, and an additional submission progressing in China, CBSC's mission is to deliver cardiac monitoring solutions worldwide. Ankündigung • Oct 03
CB Scientific, Inc. Announces Chief Financial Officer Changes CB Scientific, Inc. announced that the Company's Board of Directors appointed Mr. William "Trip" Thomas as its Chief Financial Officer effective October 1, 2024. Mr. Thomas is replacing Ms. Brooke Turk who formally tendered her resignation effective September 30, 2024. Ms. Turk's resignation was not the result of any disagreement or conflict with the Company. Mr. Thomas earned a Bachelor of Science degree in Accounting from the University of Tampa and holds a Bachelor of Science degree in Agribusiness from the University of Florida. He is a licensed Certified Public Account in the State of Florida. Ankündigung • Sep 07
CB Scientific, Inc. Announces FDA 510(k) Submission of Enhanced myCam Cardiac Event Monitor CB Scientific, Inc. announced that it has completed the regulatory testing phase of its latest myCam cardiac event monitor design and has formally tendered a 510(k) submission for Clearance to Market to the U.S. Food and Drug Administration (FDA). The company anticipates a response from the FDA for this 510(k) submission in approximately 90 to 120 days. During the review process, CBSC looks forward to collaborating with the FDA in a concerted effort to obtain Clearance to Market for the new myCam product as quickly as possible. Upon receiving FDA clearance, the company intends to market the device domestically, as well as internationally throughout Asia, Latin America, India and the Middle East, each of which require FDA certification. Ankündigung • Mar 05
CB Scientific, Inc. Announces Appointment of Jeslie Chui as New Director for Asia Pacific CB Scientific. Inc. announced the appointment of Jeslie Chui as Director of Business Development Asia Pacific for CB Scientific Inc. effective March 1, 2021. In this position Mr. Chui will work to increase company recognition and awareness of CBSC and its subsidiary My-Cardia, identify and develop corporate strategies for expansion and the associated marketing platforms to support these strategies, and assist in corporate fundraising in the region. Through his various entrepreneurial roles in Hong Kong and China, Jeslie Chui has been instrumental in raising venture capital including financial advisory and business development for companies from a wide variety of industries throughout his career. For more than twenty years, Mr. Chui has been a renowned veteran financial market professional in the Asia Pacific region. His considerable knowledge and extensive work experience include new business development, IPO advisory, Deal structuring, private equity funding, and merger and acquisitions. Strategic management planning, product development, information system implementation and management, and legal compliance are other areas of his expertise. Throughout his career Jeslie has held positions with Mithera Capital, a US based Private Equity, as their Chief Marketing Officer and Head of Asia Pacific market; Chief Strategic Officer for Zhong Tai International Financial Holdings Ltd.; and Head of Wealth Management for China Galaxy International (a subsidiary of China Galaxy Securities) to name a few. In addition to his new role with CBSC, Mr. Chui also serves as the Head of Corporate Advisory Services for CCTH, a founding member of AG China. He has earned several academic degrees including a Master of Engineering in Electronic Commerce from The University of Hong Kong; Executive Master of Business Administration from The Chinese University of Hong Kong; Master of Science in Investment Management from The Hong Kong University of Science and Technology; Master of Law (LLM) in Chinese Business Law from The Chinese University of Hong Kong; and Master of Corporate Governance with Distinction from the Hong Kong Polytechnic University. Jeslie Chui is also an Adjunct Professor for the College of Business at the City University of Hong Kong and an Honorary Professor at Huashang College for the Guangdong University of Finance and Economics and has authored 24 books on investment products and corporate finance. Ankündigung • Feb 24
CB Scientific, Inc. (OTCPK:CBSC) has signed a definitive agreement to acquire Cardiolink Corporation. CB Scientific, Inc. (OTCPK:CBSC) has signed a definitive agreement to acquire Cardiolink Corporation on February 23, 2021. The deal is expected to close by May 2021. Ankündigung • Dec 30
CB Scientific. Inc. Announces Addition of Dozens of New Device Clinical Trials of my-Cam Device and New Hospital Monitoring Contracts Through Mango Wellness Co., Ltd. and My Cardia Thailand Co., Ltd CB Scientific. Inc. announced the addition of dozens of new device clinical trials of its my-Cam device and new hospital monitoring contracts through the Company’s authorized distributor, Mango Wellness Co. Ltd. (MWC) and My Cardia Thailand Co. Ltd. (MCT) in Thailand. Mango Wellness Co. Ltd.’s successful participation as an exhibitor at the Royal College of Physicians of Thailand Annual Conference in Pattaya, Thailand, Oct. 29-31, and again at the Thailand Cardiologist Annual Conference in Hua Hin, Thailand, Dec. 10-12, produced overwhelming interest from more than 160 physicians who have requested on-site evaluations of the Company’s my-Cam monitor and my-Cardia software portal in these two regions of Thailand. Mango Wellness Co. Ltd. and My Cardia Thailand anticipate adding 100 contracted hospitals in the first quarter of 2021, totaling more than 1,000 ambulatory remote cardiac event monitoring tests during this time. Ankündigung • Oct 10
CB Scientific, Inc. Announces the Launch of My-Cardia ECG Products and Services in Thailand CB Scientific. Inc. announces the targeted start of cardiac lab services operations in the country of Thailand through the Company’s exclusive authorized distributor, Mango Wellness Co., Ltd. (MWC) and My Cardia Thailand Co., Ltd. (MCT), beginning Oct. 29, 2020. Under terms of the distribution agreement, Mango Wellness Co., Ltd. and My Cardia Thailand Co., Ltd. will be the exclusive distributor for CBSC’s proprietary FDA and CE-cleared EKG my-Cam Cardiac Event Monitor, the interactive cloud-based My-Cardia acquisition software, and the associated smartphone apps for both iOS and Android platforms in Thailand. The My-Cardia product line is designed specifically for the Remote Cardiac Ambulatory ECG market to help in the detection of abnormal heart rhythms while providing improved compliance for the patient, as well as more timely, convenient and accurate information for the physician. The distribution agreement may be expanded with additional products and territories in the future. Financial terms of the agreement were not disclosed. CB Scientific plans to make further announcements to keep its shareholders, industry participants and the public markets informed through press releases and regulatory filings as new developments occur. Ankündigung • Sep 24
CB Scientific, Inc. (OTCPK:CBSC) acquired Operating Business Assets of Prevent Health Care International Corp. from Prevent Health Care International Corp. CB Scientific, Inc. (OTCPK:CBSC) acquired Operating Business Assets of Prevent Health Care International Corp. from Prevent Health Care International Corp. on September 22, 2020.
CB Scientific, Inc. (OTCPK:CBSC) completed the acquisition of Operating Business Assets of Prevent Health Care International Corp. from Prevent Health Care International Corp. on September 22, 2020.